This is Thomas Sullivan - Policy & Medicine Writing Staff's Typepad Profile.
Join Typepad and start following Thomas Sullivan - Policy & Medicine Writing Staff's activity
Join Now!
Already a member? Sign In
Thomas Sullivan - Policy & Medicine Writing Staff
Columbia, Maryland
Former political consultant who founded Rockpointe, Inc. a bio-medical education company in 1995.
Interests: marketing, politics, baseball, cycling, medicine, university of florida sports, medical education, track and cross country, driving kids to various practices
Recent Activity
Image
Eligible hospitals and critical access hospitals participating in the Hospital Inpatient Quality Reporting program and/or the Medicare EHR Incentive Program will have extra time for submission of electronic clinical quality measures. In a January 17, 2017 blog post, Kate Goodrich,... Continue reading
Posted 3 hours ago at Policy and Medicine
Image
On February 8, 2017, three organizations called on the United States Food and Drug Administration (FDA) to overhaul a newly finalized regulation giving the agency wide latitude to police off-label promotion, saying it contains abrupt and unconstitutional policy changes. The... Continue reading
Posted yesterday at Policy and Medicine
Image
Valeant Pharmaceuticals, Inc. has had quite the year - they have been under scrutiny since October 2015. However, in November 2016, one former Valeant executive and one former Philidor executive, were arrested and charged with criminal complaints. This article outlines... Continue reading
Posted yesterday at Policy and Medicine
Image
The Centers for Medicare and Medicaid Services (CMS) released a new report to Congress prepared by the CMS Innovation Center (CMMI) highlighting its achievements since its start in 2010 and laying out plans for implementation of future models. In conjunction... Continue reading
Posted 2 days ago at Policy and Medicine
Image
Right before the inauguration of the new President, the Centers for Medicare & Medicaid Services (CMS) finalized new Innovation Center models. The announcement finalizes significant new policies related to: (1) cardiac care; three new payment models will support clinicians in... Continue reading
Posted 3 days ago at Policy and Medicine
Image
There are strong indications that 2017 is already trending towards a banner year for industry compliance, including most notably the continued and active efforts by the U.S. Department of Justice (“DOJ”), U.S. Securities and Exchange Commission (“SEC”) and other government... Continue reading
Posted 3 days ago at Policy and Medicine
Image
On January 12, 2017, during the second session of Medicare Payment Advisory Commission’s (MedPAC’s) January meeting, MedPAC Commissioners evaluated current data concerning trends in Medicare Part D spending and discussed future direction for studies regarding updating the program to reflect... Continue reading
Posted 6 days ago at Policy and Medicine
Image
When it comes to corruption, Life Sciences companies are a frequent target of investigation and enforcement. The French enactment of Sapin II is the latest in a long line of laws to combat corruption. This article explores Sapin II and... Continue reading
Posted 6 days ago at Policy and Medicine
Image
Mere days before President Donald Trump was sworn into office, when any national action could (or would) be taken on drug pricing, Governor Andrew Cuomo of New York took the matter into his own hands. On January 11, 2017, he... Continue reading
Posted 7 days ago at Policy and Medicine
Image
The American Board of Internal Medicine (ABIM) is providing more choice to physicians who are working to maintain their board certification. ABIM has decided to take this step after physicians asked for more flexible options that affirm to themselves, their... Continue reading
Posted Feb 15, 2017 at Policy and Medicine
Image
2016 was the year of the price increase, as leading industry players experienced significant public outrage over what appeared to be extreme price increases. What is compliance’s role when it comes to price increases? Does the ethics and compliance function... Continue reading
Posted Feb 15, 2017 at Policy and Medicine
Image
We have previously written about Connecticut policy that was aimed at reporting payments from pharmaceutical and device manufacturers to nurse practitioners. Back when the law was originally passed, Connecticut planned to require pharmaceutical and device manufacturers to report payments and... Continue reading
Posted Feb 14, 2017 at Policy and Medicine
Image
Two prescription drug wholesalers – AmerisourceBergen Corp. and Cardinal Health Inc. – will pay $16 million and $20 million, respectively, to resolve West Virginia’s claims relating to their distribution of controlled substances in the state, according to Governor Earl Ray... Continue reading
Posted Feb 13, 2017 at Policy and Medicine
Image
In efforts to understand the rising cost of some drugs, Patient Assistance programs, particularly independent foundations, have become a focus of government investigations. This article explains what PAPs are, why they may be viewed as suspect and provides tips for... Continue reading
Posted Feb 13, 2017 at Policy and Medicine
Image
Recently, the Food and Drug Administration (FDA) finalized guidance detailing its approach to assigning non-proprietary names to biologics and biosimilars. The guidance, titled “Nonproprietary Naming of Biological Products,” finalizes an August 2015 draft of the same title. In the final... Continue reading
Posted Feb 10, 2017 at Policy and Medicine
Image
The United States Department of Health and Human Services (HHS) Office of Inspector General (OIG) recently published a report, “Early Implementation Review: CMS’s Management of the Quality Payment Program.” The report can be summed up by noting that CMS has... Continue reading
Posted Feb 9, 2017 at Policy and Medicine
Image
We have taken an interest in the growing biosimilars market in the United States. Recently, we covered the Friends of Cancer Research event, “The Future of the U.S. Biosimilars Market: Development, Education, and Utilization,” a half-day forum that brought together... Continue reading
Posted Feb 8, 2017 at Policy and Medicine
Image
As reported by Regulatory Focus, the FDA announced the “safety labeling changes” (SLC) program. It will be reportedly managed by the Center for Drug Evaluation and Research’s (CDER) Office of Communications. This program includes a database that provides public data... Continue reading
Posted Feb 7, 2017 at Policy and Medicine
Image
An article in the Philadelphia Business Journal published in early January 2017 focused on Open Payments and payment information available to the public, and how the public availability of the data is affecting doctors and the way they treat patients.... Continue reading
Posted Feb 6, 2017 at Policy and Medicine
Image
On February 3, 2017, the Department of Justice (DOJ) announced that False Claims Act (FCA) penalties will once again be increasing, effective immediately. Pursuant to the 2015 budget bill, which requires annual re-indexing of FCA penalties for inflation, the minimum... Continue reading
Posted Feb 6, 2017 at Policy and Medicine
Image
Walgreen Co. (“Walgreens”) has agreed to pay $50 million to settle allegations that it gave kickbacks to government health care beneficiaries who it enrolled in its Prescription Savings Club (PCS) discount and incentives program. The government specifically alleges that Walgreens... Continue reading
Posted Feb 3, 2017 at Policy and Medicine
Image
Medical device maker Zimmer Biomet Holdings, Inc., agreed to pay $30.5 million to resolve Department of Justice (DOJ) and Securities and Exchange Commission (SEC) investigations into the company’s “repeat” violations of the Foreign Corrupt Practices Act (FCPA). The $30.5 million... Continue reading
Posted Feb 2, 2017 at Policy and Medicine
Image
The Centers for Medicare and Medicaid Services (CMS finalized) the 2017 Medicare Physician Fee Schedule (PFS) rule. This rule, which took effect on January 1, 2017, updates payment policies and rates for services furnished under the PFS. A CMS fact... Continue reading
Posted Feb 1, 2017 at Policy and Medicine
Image
Mallinckrodt ARD Inc., formerly known as Questcor Pharmaceuticals, Inc., and its parent company, Mallinckrodt plc, have agreed to pay $100 million to settle Federal Trade Commission (FTC) charges that they violated antitrust laws when Questcor acquired the rights to a... Continue reading
Posted Jan 31, 2017 at Policy and Medicine
Image
On Tuesday, January 24, 2017, the Senate Committee on Finance held a hearing to consider the nomination of Representative Thomas Price, M.D., to be Secretary of the Department of Health and Human Services (HHS). The hearing was the last for... Continue reading
Posted Jan 30, 2017 at Policy and Medicine